- Home
- HRMY vs ZGN Comparison
HRMY vs ZGN Comparison
Compare HRMY & ZGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | ZGN |
|---|---|---|
| Founded | 2017 | 1910 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRMY | ZGN |
|---|---|---|
| Price | $37.82 | $10.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $51.33 | $10.98 |
| AVG Volume (30 Days) | ★ 779.7K | 638.0K |
| Earning Date | 11-04-2025 | 09-05-2025 |
| Dividend Yield | N/A | ★ 1.32% |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | 0.43 |
| Revenue | $825,944,000.00 | ★ $2,248,050,499.00 |
| Revenue This Year | $23.11 | N/A |
| Revenue Next Year | $16.15 | $5.08 |
| P/E Ratio | ★ $11.94 | $24.47 |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $25.52 | $6.05 |
| 52 Week High | $40.93 | $11.00 |
Technical Indicators
Market Signals| Indicator | HRMY | ZGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 55.66 |
| Support Level | $37.12 | $10.18 |
| Resistance Level | $40.87 | $10.68 |
| Average True Range (ATR) | 1.36 | 0.30 |
| MACD | -0.32 | -0.03 |
| Stochastic Oscillator | 40.59 | 52.84 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.